Ian has been covering a broad range of topics across the Japanese and Asian pharma industry, including corporate, M&A, R&D, pricing and policy developments, since 1988. After a stint as Tokyo-based Japan and Asia editor for Scrip, in 2014 he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet). In his current position, he directs regional coverage for Scrip and Pink Sheet and manages a multinational, on-the-ground team. Ian is a recipient of multiple internal and external awards and a regular participant in APAC conferences, webinars and events, and produces regular podcasts. He has spent the majority of his life in Asia, having grown up in Hong Kong, and enjoys cycling and music.
Latest from Ian Haydock
In this week's episode: Marks on Trump’s threat to FDA; Amgen’s Phase II MariTide data lack clarity; Roche’s Poseida buyout; Roche’s CMO on his biotech lessons; and what Trump 2.0 might mean for India.
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a new Citeline White Paper shows.
In this week's episode: Novo’s semaglutide looks good in NASH; J&J’s psoriasis drug hits multiple Phase III goals; NASH competition gets serious; China dominates APAC and increasingly global trials; and why has M&A decreased in 2024.
Billion dollar-plus global deal with Japanese partner gives Kura's lead asset development impetus while adding to Kyowa Kirin's ambitions in hematological malignancies.
Asia-Pacific continues to solidify its position as a key location for clinical trials, with China in particular dominating such activity in the region, and increasingly globally, a new Citeline White Paper shows.
In this week's episode: muscling into the obesity market; AbbVie’s schizophrenia failure; Bayer will not take risky bets; generally strong Q2 for Japanese majors; and AstraZeneca juggles China and growth questions.